Editorial
Enhance the FDA's Postmarketing Drug Surveillance System of Adverse Effects through the Electronic Healthcare Data
Xianglin L Du*
Division of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, Texas, USA
- Corresponding Author:
- Xianglin L Du
Division of Epidemiology
Human Genetics, and Environmental Sciences
School of Public Health
University of Texas Health Science Center at Houston
1200 Herman Pressler Drive
RAS-E631, Houston, TX 77030, USA
Tel: 713-500-9956
Fax: 713-500-9264
E-mail: [email protected]
Received Date: October 04, 2012; Accepted Date: October 07, 2012; Published Date: October 10, 2012
Citation: Du XL (2012) Enhance the FDA’s Postmarketing Drug Surveillance System of Adverse Effects through the Electronic Healthcare Data. Epidemiol 2:e104. doi:10.4172/2161-1165.1000e104
Copyright: © 2012 Du XL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Du XL (2012) Enhance the FDA’s Postmarketing Drug Surveillance System of Adverse Effects through the Electronic Healthcare Data. Epidemiol 2:e104.
